1-morpholin-4-yloctadec-9-en-1-one

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: 1-morpholin-4-yloctadec-9-en-1-one
• 化学式: C₂₂H₄₁NO₂
• 分子量: 351.573
• InChiKey: RZLQCNYCMRDLBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.8
• 重原子数：
  25
• 可旋转键数：
  15
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.86
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  丙基溴化镁 、 1-morpholin-4-yloctadec-9-en-1-one 在 cerium(III) chloride 作用下， 以 四氢呋喃 为溶剂， 反应 3.5h， 以90%的产率得到henicos-11-en-4-one
  参考文献：
  名称：

  将有机铈试剂添加到吗啉酰胺中：南美白桦（Achaea janata）重要信息素成分的合成。

  摘要：

  易于制备的吗啉酰胺与有机铈试剂以高收率结合，可制得酮。即使在存在高位阻的底物和试剂的情况下，由干氯化铈（III）和有机镁或有机锂化合物在-78摄氏度下制得的有机金属化合物也可以干净地添加到吗啉酰胺中。起始原料的低成本使得这种新的合成方案对于制备生物学上重要的信息素非常有趣。

  DOI：

  10.1021/jo0263061
• 作为产物：
  描述：

  油酸 在 吡啶 、 氯化亚砜 作用下， 以 氯仿 、 苯 为溶剂， 反应 44.0h， 生成 1-morpholin-4-yloctadec-9-en-1-one
  参考文献：
  名称：

  将有机铈试剂添加到吗啉酰胺中：南美白桦（Achaea janata）重要信息素成分的合成。

  摘要：

  易于制备的吗啉酰胺与有机铈试剂以高收率结合，可制得酮。即使在存在高位阻的底物和试剂的情况下，由干氯化铈（III）和有机镁或有机锂化合物在-78摄氏度下制得的有机金属化合物也可以干净地添加到吗啉酰胺中。起始原料的低成本使得这种新的合成方案对于制备生物学上重要的信息素非常有趣。

  DOI：

  10.1021/jo0263061

文献信息

• Synthesis of Medicinally Interesting Polyfluoro Ketones via Perfluoroalkyl Lithium Reagents
  作者：Christoforos G. Kokotos、Constantinos Baskakis、George Kokotos

  DOI：10.1021/jo801469x

  日期：2008.11.7

  The addition of (pentafluoroethyl)- and (heptafluoropropyl)lithium to various acyl derivatives was studied. Weinreb and morpholine amides led to polyfluoro ketones in high to quantitative yields in short reaction times. Derivatives of 2-fluorocarboxylic acids may produce 1,1,1,2,2,4-hexafluoro ketones and 1,1,1,2,2,3,3,5-octafluoro ketones. The methodology can provide inhibitors for various lipolytic

  研究了向各种酰基衍生物中添加（五氟乙基）-和（七氟丙基）锂。Weinreb和吗啉酰胺可在短反应时间内以高产率到定量产率产生多氟酮。2-氟羧酸的衍生物可产生1,1,1,2,2,4-六氟酮和1,1,1,2,2,3,3,5-八氟酮。该方法可以为各种脂解酶（包括磷脂酶A2）提供抑制剂。
• ANTIINFLAMMATORY 2-OXOTHIAZOLES
  申请人：Avexxin AS

  公开号：EP3431084A1

  公开（公告）日：2019-01-23

  A compound of formula (I) wherein X is O or S; R1 is H, OH, SH, nitro, NH2, NHC1-6alkyl, N(C1-6alkyl)2, halo, haloC1-6alkyl, CN, C1-6-alkyl, OC1-6alkyl, C1-6alkylCOOH, C1-6alkylCOOC1-6alkyl, C2-6-alkenyl, C3-10cycloalkyl, C6-10aryl, C1-6alkylC6-10aryl, heterocyclyl, heteroaryl, CONH2, CONHC1-6alkyl, CON(C1-6alkyl)2, OCOC1-6alkyl, or is an acidic group, such as a group comprising a carboxyl, phosphate, phosphinate, sulfate, sulfonate, or tetrazolyl group; R2 is as defined for R1 or R1 and R2 taken together can form a 6-membered aromatic ring optionally substituted by up to 4 groups R5; R3 is H, halo (preferably fluoro), or CHal3 (preferably CF3); each R5 is defined as for R1; V1 is a covalent bond or a C1-20alkyl group, or C2-20-mono or multiply unsaturated alkenyl group; said alkyl or alkenyl groups being optionally interupted by one or more heteroatoms selected from O, NH, N(C1-6 alkyl), S, SO, or SO2; M1 is absent or is a C5-10 cyclic group or a C5-15 aromatic group; and R4 is H, halo, OH, CN, nitro, NH2, NHC1-6alkyl, N(C1-6alkyl)2, haloC1-6alkyl, a C1-20alkyl group, or C2-20-mono or multiply unsaturated alkenyl group, said C1-20alkyl or C2-20alkenyl groups being optionally interupted by one or more heteroatoms selected from O, NH, N(C1-6 alkyl), S, SO, or SO2; with the proviso that the group V1M1R4 as a whole provides at least 4 backbone atoms from the C(R3) group; or a salt, ester, solvate, N-oxide, or prodrug thereof; for use in the treatment of a chronic inflammatory condition.

  式 (I) 的化合物 其中 X 是 O 或 S； R1是H、OH、SH、硝基、NH2、NHC1-6烷基、N(C1-6烷基)2、卤素、卤代 C1-6烷基、CN、C1-6烷基、OC1-6烷基、C1-6烷基COOH、C1-6烷基COOC1-6烷基、C2-6烯基、C3-10环烷基、C6-10芳基、C1-6烷基C6-10芳基、杂环烷基、杂芳基、CONH2、CONHC1-6烷基、CON(C1-6烷基)2、OCOC1-6烷基或酸性基团，如包含羧基、磷酸基、膦酸 基、硫酸基、磺酸基或四唑基的基团； R2 如 R1 所定义，或 R1 和 R2 可共同形成一个最多被 4 个基团 R5 任选取代的 6 元芳香环； R3 是 H、卤代（最好是氟代）或 CHal3（最好是 CF3）； 每个 R5 的定义与 R1 相同； V1 是共价键或 C1-20 烷基或 C2-20 单不饱和或多不饱和烯基；所述烷基或烯基任选被选自 O、NH、N（C1-6 烷基）、S、SO 或 SO2 的一个或多个杂原子所取代； M1 不存在或为 C5-10 环状基团或 C5-15 芳香基团；以及 R4 是 H、卤素、OH、CN、硝基、NH2、NHC1-6烷基、N(C1-6烷基)2、卤代 C1-6烷基、C1-20烷基或 C2-20 单不饱和或多不饱和烯基，所述 C1-20 烷基或 C2-20 烯基任选被一个或多个选自 O、NH、N(C1-6烷基)、S、SO 或 SO2 的杂原子间隔； 但整个基团 V1M1R4 至少有 4 个来自 C（R3）基团的骨架原子； 或其盐、酯、溶剂、N-氧化物或原药； 用于治疗慢性炎症。
• 2-oxothiazole compounds and method of using same for chronic inflammatory disorders
  申请人：Avexxin AS

  公开号：US10370344B2

  公开（公告）日：2019-08-06

  The invention provides compounds of formula (I) wherein X is O or S; R1 is H, OH, SH, nitro, NH2, NHC1-6alkyl, N(C1-6alkyl)2, halo, haloC1-6alkyl, CN, C1-6-alkyl, OC1-6alkyl, C1-6alkylCOOH, C1-6alkylCOOC1-6alkyl, C2-6-alkenyl, C3-10cycloalkyl, C6-10aryl, C1-6alkylC6-10aryl, heterocyclyl, heteroaryl, CONH2, CONHC1-6alkyl, CON(C1-6alkyl)2, OCOC1-6alkyl, or is an acidic group, such as a group comprising a carboxyl, phosphate, phosphinate, sulfate, sulfonate, or tetrazolyl group; R2 is as defined for R1 or R1 and R2 taken together can form a 6-membered aromatic ring optionally substituted by up to 4 groups R5; R3 is H, halo (preferably fluoro), or CHal3 (preferably CF3); each R5 is defined as for R1; V1 is a covalent bond, —O—, or a C1-20alkyl group, or C2-20-mono or multiply unsaturated alkenyl group; said alkyl or alkenyl groups being optionally interrupted by one or more heteroatoms selected from O, NH, N(C1-6 alkyl), S, SO, or SO2; M1 is absent or is a C5-10 cyclic group or a C5-15 aromatic group; and R4 is H, halo, OH, CN, nitro, NH2, NHC1-6alkyl, N(C1-6alkylh, haloC1-6alkyl, a C1-20alkyl group, or C2-20-mono or multiply unsaturated alkenyl group, said C1-20alkyl or C2-20oalkenyl groups being optionally interrupted by one or more heteroatoms selected from O, NH, N(C1-6 alkyl), S, SO, or SO2; with the proviso that the group V1M1R4 as a whole provides at least 4 backbone atoms from the C(R3) group; or a salt, ester, solvate, N-oxide, or prodrug thereof; for use in the treatment of a chronic inflammatory condition.

  本发明提供了式 (I) 的化合物 其中 X 是 O 或 S； R1是H、OH、SH、硝基、NH2、NHC1-6烷基、N(C1-6烷基)2、卤素、卤代C1-6烷基、CN、C1-6烷基、OC1-6烷基、C1-6烷基COOH、C1-6烷基COOC1-6烷基、C2-6烯基、C3-10环烷基、C6-10芳基、C1-6烷基C6-10芳基、杂环烷基、杂芳基、CONH2、CONHC1-6烷基、CON(C1-6烷基)2、OCOC1-6烷基或酸性基团，如包含羧基、磷酸基、膦酸 基、硫酸基、磺酸基或四唑基的基团； R2 如 R1 所定义，或 R1 和 R2 可共同形成一个最多被 4 个基团 R5 任选取代的 6 元芳香环； R3 是 H、卤代（最好是氟代）或 CHal3（最好是 CF3）； 每个 R5 的定义与 R1 相同； V1 是共价键、-O-、或 C1-20 烷基、或 C2-20 单或多元不饱和烯基；所述烷基或烯基可选择被一个或多个选自 O、NH、N（C1-6 烷基）、S、SO 或 SO2 的杂原子打断； M1 不存在或为 C5-10 环状基团或 C5-15 芳香基团；以及 R4 是 H、卤素、OH、CN、硝基、NH2、NHC1-6烷基、N(C1-6烷基h、卤代 C1-6烷基、C1-20烷基或 C2-20 单或多不饱和烯基，所述 C1-20 烷基或 C2-20 烯基任选被一个或多个选自 O、NH、N(C1-6烷基)、S、SO 或 SO2 的杂原子打断； 但整个基团 V1M1R4 至少有 4 个来自 C（R3）基团的骨架原子； 或其盐、酯、溶液剂、N-氧化物或原药；用于治疗慢性炎症。
• ANTI INFLAMMATORY 2-OXOTHIAZOLES AND 2 -OXOOXAZOLES
  申请人：Avexxin AS

  公开号：EP2482815A1

  公开（公告）日：2012-08-08
• COMPOUND
  申请人：Kokotos George

  公开号：US20110136879A1

  公开（公告）日：2011-06-09

  The invention provides compounds of formula (I) wherein X is O or S; R 1 is H, OH, SH, nitro, NH 2 , NHC 1-6 alkyl, N(C 1-6 alkyl) 2 , halo, haloC 1-6 alkyl, CN, C 1-6 -alkyl, OC 1-6 alkyl, C 1-6 alkylCOOH, C 1-6 alkylCOOC 1-6 alkyl, C 2-6 -alkenyl, C 3-10 cycloalkyl, C 6-10 aryl, C 1-6 alkylC 6-10 aryl, heterocyclyl, heteroaryl, CONH 2 , CONHC 1-6 alkyl, CON(C 1-6 alkyl) 2 , OCOC 1-6 alkyl, or is an acidic group, such as a group comprising a carboxyl, phosphate, phosphinate, sulfate, sulfonate, or tetrazolyl group; R 2 is as defined for R 1 or R 1 and R 2 taken together can form a 6-membered aromatic ring optionally substituted by up to 4 groups R 5 ; R 3 is H, halo (preferably fluoro), or CHal 3 (preferably CF 3 ), each R 5 is defined as for R 1 ; V 1 is a covalent bond or a C 1-20 alkyl group, or C 2-20 -mono or multiply unsaturated alkenyl group; said alkyl or alkenyl groups being optionally interupted by one or more heteroatoms selected from O, NH, N(C 1-6 alkyl), S, SO, or SO 2 ; M 1 is absent or is a C 5-10 cyclic group or a C 5-15 aromatic group; and R 4 is H, halo, OH, CN, nitro, NH 2 , NHC 1-6 alkyl, N(C 1-6 alkyl) 2 , haloC 1-6 alkyl, a C 1-20 alkyl group, or C 2-20 -mono or multiply unsaturated alkenyl group, said C 1-20 alkyl or C 2-20 alkenyl groups being optionally interupted by one or more heteroatoms selected from O, NH, N(C 1-6 alkyl), S, SO, or SO 2 ; with the proviso that the group V 1 M 1 R 4 as a whole provides at least 4 backbone atoms from the C(R 3 ) group; or a salt, ester, solvate, N-oxide, or prodrug thereof; for use in the treatment of a chronic inflammatory condition.